Haitao Gu

Prof. Dr. Haitao Gu

Department of Gastrointestinal surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China., Chongqing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ZXZhiquan Xu
Zhiquan Xu
LXLing Xiang
Ling Xiang
RWRong Wang
Rong Wang
YXYongfu Xiong
Yongfu Xiong
HZHe Zhou
He Zhou
LPLinglong Peng
Linglong Peng
Background. Currently, immunotherapy is widely used for breast cancer (BC) patients, and tumor mutation burden (TMB) is regarded as a valuable independent predictor of response to immunotherapy. However, specific gene mutations and their relationship with TMB and tumor‐infiltrating immune cells in BC are not fully understood. Methods. Comprehensive bioinformatic analyses were performed using data from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) datasets. Survival curves were analyzed via Kaplan‐Meier analysis. Univariate and multivariate Cox regression analyses were used for prognosis analysis. Gene set enrichment analysis (GSEA) was performed to explore regulatory mechanisms and functions. The CIBERSORT algorithm was used to calculate the tumor‐infiltrating immune cell fractions. Results. We analyzed somatic mutation data of BC from TCGA and ICGC datasets and found that 19 frequently mutated genes were reported in both cohorts, namely, SPTA1, TTN, MUC17, MAP3K1, CDH1, FAT3, SYNE1, FLG, HMCN1, RYR2 (ryanodine receptor 2), GATA3, MUC4, PIK3CA, KMT2C, TP53, PTEN, ZFHX4, MUC16, and USH2A. Among them, we observed that RYR2 mutation was significantly associated with higher TMB and better clinical prognosis. Moreover, GSEA revealed that RYR2 mutation‐enriched signaling pathways were related to immune‐associated pathways. Furthermore, based on the CIBERSORT algorithm, we found that RYR2 mutation enhanced the antitumor immune response by enriching CD8+ T cells, activated memory CD4+ T cells, and M1 macrophages. Conclusion. RYR2 is frequently mutated in BC, and its mutation is related to increased TMB and promotes antitumor immunity; thus, RYR2 may serve as a valuable biomarker to predict the immune response.

1 November 2022 in Experimental Cell Research
Verified
Journal Article
Closed access
YYYuhan Yang
Yuhan Yang
LCLei Cao
Lei Cao
ZGZengya Guo
Zengya Guo
HGHaitao Gu
Haitao Gu
KZKundong Zhang
Kundong Zhang
ZQZhengjun Qiu
Zhengjun Qiu

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YZYongchuan Zhang
Yongchuan Zhang
YZYinglin Zhang
Yinglin Zhang
JWJin Wang
Jin Wang
HGHaitao Gu
Haitao Gu
Background. Whether and how amarogentin suppresses the angiogenesis effect in liver cancer cells after insufficient radiofrequency ablation (iRFA) are still poorly studied. Methods. The number of liver cancer stem cells (LCSCs) and the level of vascular endothelial growth factor A (VEGFA) were assessed in liver cancer tissue after iRFA. Then, CD133‐positive cells were detected in iRFA models of HepG2 and Huh7 cell lines treated with amarogentin. Tube formation assays were applied to observe the antiangiogenesis effects of amarogentin. In addition, the angiogenesis‐related molecules p53, delta‐like ligand 4 (Dll4), and Notch1 were detected in the iRFA cells and mouse models treated with amarogentin. Results. The mRNA and protein expression levels of CD133 and VEGFA were significantly higher in the residual liver cancer tissue than in the liver cancer tissues treated by hepatectomy. Amarogentin then markedly decreased the percentage of CD133‐positive cells in the iRFA model in both HepG2 and Huh7 cell lines. The number of tubules formed by human umbilical vein endothelial cells (HUVECs) was significantly decreased by amarogentin. Inversely, the antiangiogenesis effect of amarogentin was counteracted after p53 silencing in the iRFA cell models. Conclusion. Amarogentin prevents the malignant transformation of liver cancer after iRFA via affecting stemness and the p53‐dependent VEGFA/Dll4/Notch1 pathway to inhibit cancer cell angiogenesis.

18 July 2024 in Public Health
Verified
Journal Article
Closed access
XRX. Ren
X. Ren
YXY. Xiao
Y. Xiao
LXL. Xiang
L. Xiang
LPL. Peng
L. Peng
YTY. Tang
Y. Tang
HGHaitao Gu
Haitao Gu

5 December 2022 in iScience
Verified
Journal Article
Open access
CWChuntao Wu
Chuntao Wu
BHBeiyuan Hu
Beiyuan Hu
LWLei Wang
Lei Wang
XWXia WU
Xia WU
HGHaitao Gu
Haitao Gu
JLJiang Long
Jiang Long
Lipid metabolism is extensively reprogrammed in pancreatic ductal adenocarcinoma (PDAC). Stearoyl-coenzyme A desaturase (SCD) is a critical lipid regulator that was unexplored in PDAC. Here, we characterized the existence of cancer-associated fibroblasts (CAFs) with high SCD expression, and revealed them as an unfavorable prognostic factor. Therefore, primary CAFs and pancreatic cancer cells were harvested and genetically labeled. The mixture of CAFs and cancer cells were co-injected into scd-/-; prkdc-/-, or hIGF1/INS-expressing zebrafish to generate patient-derived xenograft models (zPDX). The models were aligned in 3D-printed chips for semi-automatic drug administration and high-throughput scanning. The results showed that chaperoning of the SCD-high CAFs significantly improved the drug resistance of pancreatic cancer cells against gemcitabine and cisplatin, while the administration of SCD inhibitors neutralized the protective effect. Our studies revealed the prognostic and therapeutic value of stromal SCD in PDAC, and proposed the application of zPDX model chips for drug testing.

25 August 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
LPLinglong Peng
Linglong Peng
YXYongfu Xiong
Yongfu Xiong
RWRong Wang
Rong Wang
LXLing Xiang
Ling Xiang
HZHe Zhou
He Zhou
HGHaitao Gu
Haitao Gu
Long-term tumor-initiating cells (LT-TICs) are viewed as a quantifiable target for colon cancer therapy owing to their extensive self-renewal and tumorigenic and metastatic capacities. However, it is unknown which subpopulation of colon cancer cells contains LT-TICs. Here, based on the methods for isolating and identifying cancer stem cells (CSCs) and the functional features of LT-TICs, we aimed to identify a subpopulation of LT-TICs. Among the six cell lines assessed, our results showed that CD133 and CD44 coexpression was only detected in HCT116 and HT29 cell lines. In HCT116 and HT29 cells, CD133+CD44+ cells not only shared the extensive tumorigenic potential of LT-TICs but also functionally reproduced the behaviors of LT-TICs that drive tumor metastasis formation, suggesting that CD133+CD44+ cells are a typical representation of LT-TICs in colon cancer. Mechanistically, the enhanced capacity of CD133+CD44+ cells to drive metastasis involves the upregulated expression of Wnt-, EMT-, and metastasis-related genes in these cells. Additionally, CD133+CD44+ cells presented significant chemoresistance compared with corresponding nontumorigenic CD133-CD44- cells following exposure to oxaliplatin or 5-FU. Accordingly, CD133+CD44+ cells contained lower ROS levels than CD133-CD44- cells, and the low ROS levels in CD133+CD44+ cells were related to the enhancement of antioxidant defense systems. More importantly, CD133+CD44+ cells developed less DNA damage after exposure to chemotherapeutics than CD133-CD44- cells. In conclusion, we identified a subpopulation of LT-TICs in colon cancer.